Details

Last Funding Type

Post-IPO Equity

Last Funding Money Raised

¥266M

Industries

Biotechnology,Manufacturing,Pharmaceutical

Founded date

Jun 17, 2002

Number Of Employee

1 - 10

Operating Status

Active

Liaoning Chengda Biotechnology Co., Ltd. is an international advanced virus vaccine production technology platform introduced from the United States. It was established in Shenyang in June 2002 as a high-tech enterprise. Companies adhering to the "integrity integrity, benevolence and harmony" of the core values, is committed to research and development, production and promotion of "international level, domestic leading" biological products, the main products for Chengda speed up human rabies vaccine and Chengda Libao people type B Encephalitis inactivated vaccine.



Chengda Bio was listed on the New Third Board on December 31, 2014 with a registered capital of 360 million. It is controlled by Liaoning Chengda Co., Ltd. (600739), and its profitability and appreciation potential are among the top three new board companies. The production base is located in the National High-tech Park of Weinan, Shenyang, covering an area of ​​nearly 100 acres, with a construction area of ​​over 50,000 square meters and more than 800 employees. There are 4 stock solutions workshops, 3 preparation workshops and a pilot plant. The annual production capacity of human rabies vaccine reaches 10 million, and the annual production capacity of Japanese encephalitis vaccine is 10 million. All workshops have successfully passed the 2010 national new GMP certification.



Chengda Bio is a family vaccine manufacturer. Chengda Suida rabies vaccine has always maintained a leading position in the domestic market, and has been exported to India, Pakistan, Thailand, the Philippines, Kenya, Ghana, Malawi, Georgia, etc. Countries. Chengda Libao JE vaccine is currently the only inactivated Japanese encephalitis vaccine in China and has been successfully exported to Thailand and registered in Cambodia. The bivalent renal syndrome hemorrhagic fever vaccine (Vero cells) independently developed based on the core technology platform has completed clinical research work, and the target is to obtain the production batch number in 2022 and pass the GMP acceptance.



On the one hand, Chengda Bio has accelerated the expansion of its product line, supplemented the conventional vaccine varieties at a high starting point, and actively promoted the development of multi-linked multi-valent vaccines and innovative vaccines around the country's expansion of the immunization program vaccine supply system. Chengda Bio has always adhered to the values ​​of “integrity and responsibility”, established brand awareness and reputation in both domestic and international markets, adhered to the “international level, domestic leading” product positioning, and strived to become trustworthy and respectful in the industry. A company with significant influence.